Quality of life and healthcare utilisation improvements after atrial fibrillation ablation
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ..
OBJECTIVE: Pulmonary vein isolation (PVI) guided by a standardised CLOSE (contiguous optimised lesions) protocol has been shown to increase clinical success after catheter ablation for paroxysmal atrial fibrillation (PAF). This study analysed healthcare utilisation and quality of life (QOL) outcomes from a large multicentre prospective study, measured association between QOL and atrial fibrillation (AF) burden and identified factors associated with lack of QOL improvement.
METHODS: CLOSE-guided ablation was performed in 329 consecutive patients (age 61.4 years, 60.8% male) with drug-refractory PAF in 17 European centres. QOL was measured at baseline and 12 months post-ablation via Atrial Fibrillation Effect on QualiTy of Life Survey (AFEQT) and EuroQoL EQ-5D-5L questionnaires. All-cause and cardiovascular hospitalisations and cardioversions over 12 months pre-ablation and post-ablation were recorded. Rhythm monitoring included weekly and symptom-driven trans-telephonic monitoring, plus ECG and Holter monitoring at 3, 6 and 12 months. AF burden was defined as the percentage of postblanking tracings with an atrial tachyarrhythmia ≥30 s. Continuous measures across multiple time points were analysed using paired t-tests, and associations between various continuous measures were analysed using independent sample t-tests. Each statistical test used two-sided p values with a significance level of 0.05.
RESULTS: Both QOL instruments showed significant 12-month improvements across all domains: AFEQT score increased 25.1-37.5 points and 33.3%-50.8% fewer patients reporting any problem across EuroQoL EQ-5D-5L domains. Overall, AFEQT improvement was highly associated with AF burden (p=0.009 for <10% vs ≥10% burden, p<0.001 for <20% vs ≥20% burden). Cardiovascular hospitalisations were significantly decreased after ablation (42%, p=0.001). Patients without substantial improvement in AFEQT (55/301, 18.2%) had higher AFEQT and CHA2DS2-VASc scores at baseline, and higher AF burden following PVI.
CONCLUSIONS: QOL improved and healthcare utilisation decreased significantly after ablation with a standardised CLOSE protocol. QOL improvement was significantly associated with impairment at baseline and AF burden after ablation.
TRIAL REGISTRATION NUMBER: NCT03062046.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:107 |
|---|---|
| Enthalten in: |
Heart (British Cardiac Society) - 107(2021), 16 vom: 05. Aug., Seite 1296-1302 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gupta, Dhiraj [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Atrial fibrillation |
|---|
| Anmerkungen: |
Date Completed 07.12.2021 Date Revised 14.12.2021 published: Print-Electronic ClinicalTrials.gov: NCT03062046 Citation Status MEDLINE |
|---|
| doi: |
10.1136/heartjnl-2020-318676 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325053685 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325053685 | ||
| 003 | DE-627 | ||
| 005 | 20231225191624.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/heartjnl-2020-318676 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1083.xml |
| 035 | |a (DE-627)NLM325053685 | ||
| 035 | |a (NLM)33952593 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gupta, Dhiraj |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Quality of life and healthcare utilisation improvements after atrial fibrillation ablation |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.12.2021 | ||
| 500 | |a Date Revised 14.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03062046 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. | ||
| 520 | |a OBJECTIVE: Pulmonary vein isolation (PVI) guided by a standardised CLOSE (contiguous optimised lesions) protocol has been shown to increase clinical success after catheter ablation for paroxysmal atrial fibrillation (PAF). This study analysed healthcare utilisation and quality of life (QOL) outcomes from a large multicentre prospective study, measured association between QOL and atrial fibrillation (AF) burden and identified factors associated with lack of QOL improvement | ||
| 520 | |a METHODS: CLOSE-guided ablation was performed in 329 consecutive patients (age 61.4 years, 60.8% male) with drug-refractory PAF in 17 European centres. QOL was measured at baseline and 12 months post-ablation via Atrial Fibrillation Effect on QualiTy of Life Survey (AFEQT) and EuroQoL EQ-5D-5L questionnaires. All-cause and cardiovascular hospitalisations and cardioversions over 12 months pre-ablation and post-ablation were recorded. Rhythm monitoring included weekly and symptom-driven trans-telephonic monitoring, plus ECG and Holter monitoring at 3, 6 and 12 months. AF burden was defined as the percentage of postblanking tracings with an atrial tachyarrhythmia ≥30 s. Continuous measures across multiple time points were analysed using paired t-tests, and associations between various continuous measures were analysed using independent sample t-tests. Each statistical test used two-sided p values with a significance level of 0.05 | ||
| 520 | |a RESULTS: Both QOL instruments showed significant 12-month improvements across all domains: AFEQT score increased 25.1-37.5 points and 33.3%-50.8% fewer patients reporting any problem across EuroQoL EQ-5D-5L domains. Overall, AFEQT improvement was highly associated with AF burden (p=0.009 for <10% vs ≥10% burden, p<0.001 for <20% vs ≥20% burden). Cardiovascular hospitalisations were significantly decreased after ablation (42%, p=0.001). Patients without substantial improvement in AFEQT (55/301, 18.2%) had higher AFEQT and CHA2DS2-VASc scores at baseline, and higher AF burden following PVI | ||
| 520 | |a CONCLUSIONS: QOL improved and healthcare utilisation decreased significantly after ablation with a standardised CLOSE protocol. QOL improvement was significantly associated with impairment at baseline and AF burden after ablation | ||
| 520 | |a TRIAL REGISTRATION NUMBER: NCT03062046 | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a atrial fibrillation | |
| 650 | 4 | |a catheter ablation | |
| 700 | 1 | |a Vijgen, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Potter, Tom De |e verfasserin |4 aut | |
| 700 | 1 | |a Scherr, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Van Herendael, Hugo |e verfasserin |4 aut | |
| 700 | 1 | |a Knecht, Sebastien |e verfasserin |4 aut | |
| 700 | 1 | |a Kobza, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Berte, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Sandgaard, Niels |e verfasserin |4 aut | |
| 700 | 1 | |a Albenque, Jean-Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Széplaki, Gábor |e verfasserin |4 aut | |
| 700 | 1 | |a Stevenhagen, Yorick |e verfasserin |4 aut | |
| 700 | 1 | |a Taghji, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Wright, Matt |e verfasserin |4 aut | |
| 700 | 1 | |a Duytschaever, Mattias |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Heart (British Cardiac Society) |d 1996 |g 107(2021), 16 vom: 05. Aug., Seite 1296-1302 |w (DE-627)NLM085989274 |x 1468-201X |7 nnns |
| 773 | 1 | 8 | |g volume:107 |g year:2021 |g number:16 |g day:05 |g month:08 |g pages:1296-1302 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/heartjnl-2020-318676 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 107 |j 2021 |e 16 |b 05 |c 08 |h 1296-1302 | ||